VILNIAUS UNIVERSITETAS

ARANOTE Trial: Darolutamide Plus ADT Improves Outcomes in Metastatic Hormone-Sensitive Prostate Cancer

8 months ago

• The ARANOTE trial demonstrated that darolutamide plus androgen deprivation therapy (ADT) significantly improves radiographic progression-free survival (rPFS) in patients with metastatic hormone-sensitive prostate cancer (mHSPC). • Darolutamide-treated patients experienced a 46% reduction in the risk of radiographic progression or death compared to those receiving ADT plus placebo, with consistent benefits across subgroups. • The combination therapy also delayed time to castration-resistant prostate cancer and pain progression, while showing a favorable safety profile with lower rates of fatigue. • These findings suggest darolutamide plus ADT could become a new standard of care for mHSPC, offering an alternative to chemotherapy-based regimens.